These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1065 related items for PubMed ID: 12036392

  • 21. [Metabolic interactions with statins].
    Molden E, Asberg A.
    Tidsskr Nor Laegeforen; 2001 Jan 20; 121(2):189-93. PubMed ID: 11475198
    [Abstract] [Full Text] [Related]

  • 22. Clinical pharmacokinetics of statins.
    García MJ, Reinoso RF, Sánchez Navarro A, Prous JR.
    Methods Find Exp Clin Pharmacol; 2003 Jan 20; 25(6):457-81. PubMed ID: 12949632
    [Abstract] [Full Text] [Related]

  • 23. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
    Balasubramanian R, Maideen NMP.
    Curr Drug Metab; 2021 Jan 20; 22(5):328-341. PubMed ID: 33459228
    [Abstract] [Full Text] [Related]

  • 24. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.
    Tirkkonen T, Ryynänen A, Vahlberg T, Irjala K, Klaukka T, Huupponen R, Laine K.
    Drug Saf; 2008 Jan 20; 31(3):231-40. PubMed ID: 18302447
    [Abstract] [Full Text] [Related]

  • 25. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH, Choi JS, Choi DH.
    Pharmacology; 2011 Jan 20; 88(1-2):1-9. PubMed ID: 21709429
    [Abstract] [Full Text] [Related]

  • 26. Clinical pharmacokinetics of atorvastatin.
    Lennernäs H.
    Clin Pharmacokinet; 2003 Jan 20; 42(13):1141-60. PubMed ID: 14531725
    [Abstract] [Full Text] [Related]

  • 27. Statin safety and drug interactions: clinical implications.
    Bottorff MB.
    Am J Cardiol; 2006 Apr 17; 97(8A):27C-31C. PubMed ID: 16581325
    [Abstract] [Full Text] [Related]

  • 28. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR.
    Am J Health Syst Pharm; 1995 Aug 01; 52(15):1639-45. PubMed ID: 7583826
    [Abstract] [Full Text] [Related]

  • 29. 'Fire and forget?' - pharmacological considerations in coronary care.
    Bottorff M.
    Atherosclerosis; 1999 Sep 09; 147 Suppl 1():S23-30. PubMed ID: 10575059
    [Abstract] [Full Text] [Related]

  • 30. [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].
    Zeitlinger M, Müller M.
    Wien Med Wochenschr; 2003 Sep 09; 153(11-12):250-4. PubMed ID: 12879633
    [Abstract] [Full Text] [Related]

  • 31. [Safety profile of statins].
    Prieto JC.
    Rev Med Chil; 2001 Nov 09; 129(11):1237-40. PubMed ID: 11836874
    [Abstract] [Full Text] [Related]

  • 32. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM, Eisenberg MJ, Christopoulos S.
    Am Heart J; 2004 Jun 09; 147(6):956-65. PubMed ID: 15199341
    [Abstract] [Full Text] [Related]

  • 33. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
    Wang E, Casciano CN, Clement RP, Johnson WW.
    Pharm Res; 2001 Jun 09; 18(6):800-6. PubMed ID: 11474784
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Statins and myotoxicity: a therapeutic limitation.
    Tiwari A, Bansal V, Chugh A, Mookhtiar K.
    Expert Opin Drug Saf; 2006 Sep 09; 5(5):651-66. PubMed ID: 16907655
    [Abstract] [Full Text] [Related]

  • 36. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS, Fong NT.
    Ann Pharmacother; 1998 Oct 09; 32(10):1030-43. PubMed ID: 9793596
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
    Asberg A.
    Drugs; 2003 Oct 09; 63(4):367-78. PubMed ID: 12558459
    [Abstract] [Full Text] [Related]

  • 39. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
    Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K.
    Pharm Res; 2006 Mar 09; 23(3):506-12. PubMed ID: 16388406
    [Abstract] [Full Text] [Related]

  • 40. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
    Schachter M.
    Fundam Clin Pharmacol; 2005 Feb 09; 19(1):117-25. PubMed ID: 15660968
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.